In this study, we retrospectively analyzed clinical outcomes of patients with NSCLC whose tumors lacked clinically actionable oncogenic mutations after progressing from EGFR-TKIs and who subsequently received either Chemo+ICIs or chemotherapy with or without bevacizumab (Bev). This evidence concerns the gene EGFR and non-small cell lung carcinoma.